康泰生物公告,公司和兰州百灵生物技术有限公司研发的三价流感病毒裂解疫苗(MDCK细胞)临床试验申请获得国家药品监督管理局受理。该疫苗适用于3周岁及以上人群,可预防疫苗相关型别的流感病毒引起的流行性感冒。国内尚无三价流感病毒裂解疫苗(MDCK细胞)获批上市。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.